Litigation Details for Pfizer Inc. v. Dexcel Pharma Technologies Limited (D. Del. 2023)

Pfizer Inc. v. Dexcel Pharma Technologies Limited (D. Del. 2023)

Docket		Date Filed	2023-08-10
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To	Christopher J. Burke
Patents	7,214,695; 7,214,696; 9,770,441
Link to Docket	External link to docket

Details for Pfizer Inc. v. Dexcel Pharma Technologies Limited (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-08-10	1	Complaint	prior to the expiration of U.S. Patent Nos. 7,214,695 (“the ’695 patent”) (attached as Exhibit A), 7,214,696… 1. This is an action for patent infringement under the patent laws of the United States, Title…declaratory judgment of patent infringement under 28 U.S.C. §§ 2201 and 2202 and the patent laws of the United…7,214,696 (“the ’696 patent”) (attached as Exhibit B), and 9,770,441 (“the ’441 patent”) (attached as Exhibit…Exhibit C). These three patents are referred to collectively as “the patents-in-suit.” Case 1:23-cv-00879	External link to document
2023-08-10	3	ANDA Form	Expiration of Patent: U.S. Patent No. 7,214,695 expires on April 27, 2024. U.S. Patent No. 7,214,696 … Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …7,214,696 expires on December 19, 2023. U.S. Patent No. 9,770,441 expires on August 31, 2035.Thirty Month Stay… 10 August 2023 1:23-cv-00879 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2023-08-10	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,214,695 B2; 7,214,696 B2; 9,770,441… 10 August 2023 1:23-cv-00879 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document